Dana-Farber’s CCTI

Pioneering cancer research for personalized treatments through innovative clinical trials @DanaFarber and @HarvardMed.
Appts: 617-632-5620

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Cheryl Nelson, who works in the #CCTI_DFCI providing administrative support! She loves assisting the team with their day-to-day operations. Fun fact: she has 11 grandchildren who are her world! @DanaFarber @DanaFarberNews

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Darren Dias, a program coordinator in the #CCTI_DFCI. He provides administrative support to our CCTI staff and plans, implements, and executes CCTI events. He loves Reese’s PB cups! @DanaFarber @DanaFarberNews

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Katie Cunningham, a regulatory coordinator in the #CCTI_DFCI. She ensures that studies are in compliance with federal and international standards. Her favorite part of the job are the awesome & dedicated teammates that she works with! @DanaFarber

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Solida Pruitt-Thompson, a regulatory coordinator in the #CCTI_DFCI. She maintains protocols for audit readiness, and submits new protocols and amendments. She loves helping others through her role and enjoys reading books and taking walks. @DanaFarber

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight is Raissa Rodrigues, who works in the regulatory department of #CCTI_DFCI She ensures that CCTI studies are in compliance with FDA and GCP guidelines. She loves contributing to the process of bringing new trials and medications to patients @DanaFarber

[Dana-Farber’s CCTI @DanaFarber_CCTI]

#trialtuesday is Trial 23-044: STX-478 mutant-selective, PI3Kα small molecule inhibitor, highly selective for kinase and/or helical domain mutations in breast, gynecological, head and neck, and other solid tumors #CCTI_DFCI @DanaFarber @antgiorda
Visit: https://t.co/xL1MgJ5FVe

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Today’s #trialtuesday is led by @aloktewar of @DanaFarber_GU. #CCTI_DFCI presents Trial 23-643: USP1 inhibitor for BRCA 1/2, PALB2, RAD51C/D mutated or HSD positive solid tumors. Now in dose escalation. @DanaFarber @DanaFarberNews
Visit: https://t.co/umjiTpCGFx

[Antonio Giordano, MD PhD @antgiorda]

Dr. Glenn Hanna giving state-of-the-center for our early drug development program @danafarber_ccti 6-month tremendous growth - saying yes and saying no - to give patients more trial opportunities and treatment options. #phase1trial #CancerResearch @HeadNeckMD

[Dana-Farber’s CCTI @DanaFarber_CCTI]

For #trialtuesday, #CCTI_DFCI presents new trial 23-600 led by @FilipaLynce. IDE161, a PARG inhibitor, targets HRD and BRCA mutations in ER+ breast, endometrial, colorectal, and head and neck with these mutations. Different from PARPi. @DanaFarber
Visit: https://t.co/xL1MgJ5FVe

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight Monday is Antonio Giordano, MD, PhD. He is a breast medical oncologist and clinical director of CCTI. He enjoys working closely to his patients to select the right clinical trials for them. He also loves spending time outside with his 3 boys! @DanaFarber

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Sarah Combs, a research nurse who guides patients through their clinical trial experience while managing their side effects and being their point of contact. Her favorite part of the job is meeting different people. @DanaFarber @DanaFarberNews

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Dr. Kartik Sehgal, a head and neck medical oncologist who provides clinical care and serves as a PI for immunotherapy and antibody drug conjugates trials. He enjoys interacting with the CCTI staff and working towards a common goal @DanaFarber

[Dana-Farber’s CCTI @DanaFarber_CCTI]

For #trialtuesday,  #CCTI_DFCI presents trial 22-641 of TYRA-300, an FGFR3 specific inhibitor for patients with solid tumors and pathogenic FGFR3 gene alterations. Led by @CharleneMantia. @DanaFarber_GU @DanaFarber @DanaFarberNews
Visit: https://t.co/xL1MgJ5FVe

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Illya Dixon, who works as a CRC in the #CCTI_DFCI. His job is to ensure that all data is entered in the electronic data capture forms and respond to any queries that may be generated from the data. He enjoys sharing a good laugh with his co-workers.

[Dana-Farber’s CCTI @DanaFarber_CCTI]

For #trialtuesday, #CCTI_DFCI presents trial 23-044. STX-478 mutant-selective, PI3Kα small molecule inhibitor, highly selective for kinase domain mutations that comprise over 40% of all PI3Kα mutations in breast cancers. @DanaFarber @DanaFarberNews
Visit:https://t.co/xL1MgJ5FVe

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Zachary Medeiros, a project manager in the #DFCI_CCTI. As a Research Project Manager, Zachary oversees the activation of all new protocol’s in the CCTI. He enjoys coming to work everyday and being a part of ground breaking research.

[Dana-Farber’s CCTI @DanaFarber_CCTI]

For #trialtuesday, #CCTI_DFCI presents trial 19-670 exploring the EZH2 inhibitor tulmimetostat with slots available for ARID1A mutated endometrial cancers. Led by Dr. Alok Tewari. @DanaFarber
@DanaFarberNews
@MorphoSys
Visit https://t.co/xL1MgJ5FVe

[Dana-Farber’s CCTI @DanaFarber_CCTI]

For #trialtuesday, #CCTI_DFCI presents Trial 20-631 exploring Pembrolizumab with Enfortumab vedotin (Nectin-4 ADC) in first-line advanced #HNSCC. Led by Dr. Glenn Hanna @HeadNeckMD
@DanaFarber
@DanaFarberNews
@AstellasUS
 Visit https://t.co/xL1MgJ5FVe

[Dana-Farber’s CCTI @DanaFarber_CCTI]

Our #staffhighlight today is Alissa Skavish, a clinical research coordinator who makes sure that all necessary components of a trial are working properly. One of her favorite parts of her job is coming into work everyday and working with her team. @DanaFarber @DanaFarberNews

[Dana-Farber’s CCTI @DanaFarber_CCTI]

For #trialtuesday, #CCTI_DFCI presents Trial 23-111 exploring a novel TF-directed ADC (XB002) +/- aPD-1 or VEGFR tx for many solid tumors. TF is expressed in many tumors! Led by Dr. Haeseong Park. @HaeseongPark1
@DanaFarber @DanaFarberNews  
Visit https://t.co/xL1MgJ5FVe